Bristol-Celgene Deal Opposition Needs a Dose of Reality

Bookmark
(Bloomberg Opinion) -- Whispers of discontent around Bristol-Myers Squibb Co.’s $74 billion acquisition  of Celgene Corp. have turned into a roar.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.